Phase I study evaluating the chemosensitizing effect of everolimus administered with cytarabine and daunorubicin in patients with acute myeloid leukemia in relapse.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Everolimus (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 18 Dec 2009 Actual initiation date changed from Feb 2008 to Sep 2007 as reported by ClinicalTrials.gov.
- 08 Mar 2008 New trial centre added.
- 08 Mar 2008 Status changed from initiated to recruiting.